Protocol Ledger

NCT04984876 · Phase III · TERMINATED

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Interventional Phase III clinical trial protocol NCT04984876 sponsored by Novartis in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-07 Enrollment: 211 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04984876
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)211 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04984876
Protocol FieldVerified Registry Value
NCT IdentifierNCT04984876
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment211 participants (ACTUAL)
Registered Start Date2021-12-07
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04984876
Hospital Research SiteLocationSite Profile
Arkansas Children's HospitalLittle Rock, AROpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI